Profile

Spex Capital is a digital health and med-tech investment management firm specialized in advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally.

Profile

Spex Capital is a digital health and med-tech investment management firm specialized in advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally.

HEALTHCARE FIRST

There is today an incredible pool of talent with unexpressed potential. Many innovative ventures don’t get access to the appropriate opportunities in their early stages due to lack of funds.

We aim to bridge promising companies to help them navigate and overcome the ‘valley of death’.

HEALTHCARE FIRST

There is today an incredible pool of talent with unexpressed potential. Many innovative ventures don’t get access to the appropriate opportunities in their early stages due to lack of funds.

We aim to bridge promising companies to help them navigate and overcome the ‘valley of death’.

OUR EXPERTISE

Spex, from  specere,  latin  verb for  ‘to look at’, defines who we  are.

As thorough observers, we analyse potential  investee companies  scrupulously,  carrying  out  a  detailed due diligence to  efficiently  select and invest in them.

Our aim is to overcome these global healthcare challenges:

Our impact driven reporting metrics align with the United Nations (UN) Sustainable Development Goals

We support the guidance from the Global Impact Investing Network, IRIS+ standards, and the Impact Management Project frameworks.

OUR EXPERTISE

Spex, from  specere,  latin  verb for  ‘to look at’, defines who we  are.

As thorough observers, we analyse potential  investee companies  scrupulously,  carrying  out  a  detailed due diligence to  efficiently  select and invest in them.

Our aim is to overcome these global healthcare challenges:

Our impact driven reporting metrics align with the United Nations (UN) Sustainable Development Goals

We support the guidance from the Global Impact Investing Network, IRIS+ standards, and the Impact Management Project frameworks.

OUR STORY

Spex Capital started when serial health-tech entrepreneur Claudio D’Angelo decided to launch a new digital health and med-tech investment management firm.

Claudio spent considerable time and energy building relationships with partners who can help validate the target technologies and created an unparalleled network and ecosystem.

Spex brings together ambitious and innovative entrepreneurs from all walks of life who share one mission:

To make healthcare better.

Accelerating the healthcare digital revolution

£100
Millions of £ capital raise target

With a £100m fundraising target, Spex Capital can truly implement change in digital healthcare by investing in the most promising candidates with the pledge and capability to follow on with the more deserving companies during future rounds.

OUR STORY

Spex Capital started when serial health-tech entrepreneur Claudio D’Angelo decided to launch a new digital health and med-tech investment management firm.

Claudio spent considerable time and energy building relationships with partners who can help validate the target technologies and created an unparalleled network and ecosystem.

Spex brings together ambitious and innovative entrepreneurs from all walks of life who share one mission:

To make healthcare better.

Accelerating the healthcare digital revolution

£0
Millions of £ capital raise target

With a £100m fundraising target, Spex Capital can truly implement change in digital healthcare by investing in the most promising candidates with the pledge and capability to follow on with the more deserving companies during future rounds.

FAQs

Spex invests in digital healthcare and med-tech early stage companies.

We look at target companies with “traction”. That can come in the form of contracts, revenues, studies and validations, partnerships and more.

Thanks to our multidisciplinary team we are able to assess technologies from the medical standpoint and via a very detailed financial and commercial due diligence. We are planning to launch regular investment calls to attract hundreds of target companies and through a tested process, shortlist the most promising candidates.

We aim to make up to 15 investments per annum.
We benefit from a special partnership with the NHS – via  MedCity – and with several other stakeholders in this vertical.

We offer early stage investments with the commitment to follow on with the most promising entrepreneurs up to Series A and in few cases Series B.

We will invest in between £500k – £2m at Seed or first ticket, up to £5m at series A or second ticket and could follow up at Series B for companies we know very well.

We are specialised in digital healthcare and med-tech with an incredible flow of companies thanks to our special relationship with NHS England via MedCity. We rely heavily on an incredible panel of senior advisors with complementary experiences and expertise. SPEX also benefits from a global healthcare ecosystem via partnerships and relationships with accelerators & incubators, universities, foreign embassies, chambers of commerce, trade bodies, hospitals, payors and healthcare systems across all continents to source the highest calibre technologies worldwide. 

FAQs

Spex invests in digital healthcare and med-tech early stage companies.

We look at target companies with “traction”. That can come in the form of contracts, revenues, studies and validations, partnerships and more.

Thanks to our multidisciplinary team we are able to assess technologies from the medical standpoint and via a very detailed financial and commercial due diligence. We are planning to launch regular investment calls to attract hundreds of target companies and through a tested process, shortlist the most promising candidates.

We aim to make up to 15 investments per annum.
We benefit from a special partnership with the NHS – via  MedCity – and with several other stakeholders in this vertical.

We offer early stage investments with the commitment to follow on with the most promising entrepreneurs up to Series A and in few cases Series B.

We will invest in between £500k – £2m at Seed or first ticket, up to £5m at series A or second ticket and could follow up at Series B for companies we know very well.

We are specialised in digital healthcare and med-tech with an incredible flow of companies thanks to our special relationship with NHS England via MedCity. We rely heavily on an incredible panel of senior advisors with complementary experiences and expertise. SPEX also benefits from a global healthcare ecosystem via partnerships and relationships with accelerators & incubators, universities, foreign embassies, chambers of commerce, trade bodies, hospitals, payors and healthcare systems across all continents to source the highest calibre technologies worldwide.